Visioneering Technologies Selects Corneal Lens Corp. NZ & Contact Lens Centre Australia to Distribute NaturalVue® Brand Cont...
02 October 2018 - 11:20AM
Business Wire
Visioneering Technologies, Inc. (ASX: VTI), an innovative
US-based medical device company dedicated to developing advanced
products that improve vision, today announced that it has signed an
agreement with Corneal Lens Corporation (CLC), NZ Ltd, and its
associated company Contact Lens Centre Australia (CLCA), making
them authorized distributors of Visioneering’s innovative
NaturalVue® (etafilcon A) Brand 1 Day Contact Lenses in New Zealand
and Australia. Headquartered in Christchurch, New Zealand, CLC is a
leading Manufacturer and distributor of contact lens and vision
care products in the Australasia region, South Africa and Hong
Kong. CLCA is a distributor of leading eye care products and
contact lenses throughout Australia, and has a distribution
facility in Melbourne.
“We’re looking forward to playing a key role in bringing
Visioneering’s revolutionary products to the ANZ region,” said
Graeme Curtis, CLC Managing Director. “We are committed to
distributing only the very best vision products. The quality and
performance of the NaturalVue® 1 Day Contact Lenses, especially
with their ability to correct near-sightedness in children while
slowing or stopping its worsening in most children1, will offer a
renewed level of sight to millions of people throughout our market
– indeed, wherever their lenses are sold. We are quite proud to
represent these products.”
“We spend a great deal of time in the selection of partners and
organizations with whom we align ourselves,” said Tony Sommer,
Senior Vice President of Sales and Marketing for VTI. “Corneal Lens
is an excellent, entrepreneurial organization. Both their business
model of marketing directly to practitioners and their own high
standards for selecting the products and organizations they choose
to represent make them an ideal fit with Visioneering. We’re
thrilled to be working with them.”
About Visioneering Technologies, Inc.
Visioneering Technologies, Inc. (VTI) is a US-based medical
device company primarily engaged in the design, manufacture, sale
and distribution of a revolutionary new contact lens: the
NaturalVue® Multifocal (MF) contact lens. The NaturalVue MF contact
lens employs VTI’s Neurofocus Optics® technology, which was
developed, refined and tested over many years. The characteristics
of the NaturalVue MF contact lens allow it to be used in two of the
largest eye-care markets globally: adults with presbyopia
(age-related difficulty in seeing close objects) and children with
myopia (near-sightedness, or difficulty seeing distant
objects).
NaturalVue lenses were cleared by the FDA in late 2014 and
received the CE Mark, as well as TGA and MedSafe approval in early
2018. VTI recently commenced its US market expansion for NaturalVue
MF contact lenses, and has broadened its reach into international
markets in 2018. VTI also sells and plans additional contact lens
products.
Foreign Ownership Restriction:
VTI’s CHESS Depositary Interests (CDIs) are issued in reliance
on the exemption from registration contained in Regulation S of the
US Securities Act of 1933 (Securities Act) for offers or sales
which are made outside the US. Accordingly, the CDIs have not been,
and will not be, registered under the Securities Act or the laws of
any state or other jurisdiction in the US. The holders of VTI’s
CDIs are unable to sell the CDIs into the US or to a US person
unless the re-sale of the CDIs is registered under the Securities
Act or an exemption is available. Hedging transactions with regard
to the CDIs may only be conducted in accordance with the Securities
Act.
Forward-Looking Statements:
This announcement contains or may contain forward-looking
statements that are based on management’s beliefs, assumptions and
expectations and on information currently available to
management.
All statements that address operating performance, events or
developments that we expect or anticipate will occur in the future
are forward-looking statements. These include, without limitation,
U.S. commercial market acceptance and U.S. sales of our product as
well as, our expectations with respect to our ability to develop
and commercialize new products.
Management believes that these forward-looking statements are
reasonable when made. You should not place undue reliance on
forward-looking statements because they speak only as of the date
when made. VTI does not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. VTI may not actually
achieve the plans, projections or expectations disclosed in
forward-looking statements. Actual results, developments or events
could differ materially from those disclosed in the forward-looking
statements.
MKT-VTI-PR62
1 Cooper J, O’Connor, B, Watanabe R, Fuerst R, Berger S,
Eisenberg N, Dillehay SM. Case series analysis of myopic
progression control with a unique extended depth of focus
multifocal contact lens. Eye & Contact Lens. 2018
Sep;44(5):e16-e24.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181001006063/en/
CompanyVisioneering Technologies, Inc.Stephen Snowdy,
CEOssnowdy@vtivision.comorInvestor and media relationsWE
BuchanKyahn Williamson, +61 (3) 9866
4722kwilliamson@buchanwe.com.au
Visioneering Technologies (ASX:VTI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Visioneering Technologies (ASX:VTI)
Historical Stock Chart
From Jul 2023 to Jul 2024